new coverage: First Associates
I think this bodes well for Prometic. Carl Martel was a biotech Portfolio Manager for Caisse de Depot which is a pretty significant position in terms of weight in the marketplace. From what I understand the Caisse is still a big holder of Prometic. I think its reasonably safe to assume that he has done a considerable amount of due diligence on the company which might finally give us some coverage that is actually reflective of the company's potential.
DJN =DJ First Associates Adds 2nd Biotech Analyst
Symbol: C/AEZ AEZS C/BNC C/PLI.SV C/RCC
Industry: BTC DRG MTC SCR XDJGI XISL XTSE
Subject: DJIN DJN DJPF DJWB ANL CAC CNW DJS DJSS DJWI FCTV PEC PER
STK WEI
Market Sector: FIN NCY NND TEC
Geographic Region: CN NME ONT QBC
TORONTO (Dow Jones)--First Associates Investments Inc. bolstered its equity
research capability in the biotechnology and health-sciences sector by hiring
Carl Martel.
First Associates, a unit of Rockwater Capital Corp. (RCC.T), already has
biotechnology analyst David Washburn.
Based in Montreal, Martel initially will cover Quebec-based companies
including Ecopia Biosciences Inc. (EIA.T), Bioniche Life Sciences Inc.
(BNC.T), Aeterna Zentaris Inc. (AEZS) and ProMetic Life Sciences (PLI.SV.T).
Martel's experience on both the buy and sell sides includes a stint at the
Caisse de Depot du Quebec (CDP.YY), the Quebec pension fund, where he was in
charge of the Canadian biotech portfolios in Canada.